/ALPN
ALPN Stock - Alpine Immune Sciences, Inc.
Healthcare|BiotechnologyNASDAQ
$64.97+0.02%
+$0.01 (+0.02%) • May 17
58
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.HOLD
Medium Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.100
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).19
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.81
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+-15.3%upside
Target: $55.03
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for ALPN
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$64.32 – $65.62
TARGET (TP)$55.00
STOP LOSS$59.77
RISK/REWARD1:-1.9
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta0.97
52W High$65.00
52W Low$8.33
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|
| Revenue | $58.88M | $30.06M | $23.44M | $9.34M | $1.74M |
| Gross Profit | $-22,028,000 | $29.47M | $22.82M | $-17,850,000 | $-34,107,000 |
| Gross Margin | -37.4% | 98.0% | 97.4% | -191.2% | -1960.2% |
| Operating Income | $-44,250,000 | $-58,147,000 | $-49,859,000 | $-28,749,000 | $-43,574,000 |
| Net Income | $-32,184,000 | $-57,762,000 | $-50,333,000 | $-27,940,000 | $-42,534,000 |
| Net Margin | -54.7% | -192.1% | -214.7% | -299.3% | -2444.5% |
| EPS | $-0.64 | $-1.73 | $-1.98 | $-1.34 | $-2.32 |
Company Overview
Alpine Immune Sciences, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of protein-based immunotherapies for the treatment of cancer, autoimmune/inflammatory disorders, and other diseases. Its product pipeline includes ALPN-101, an inducible T cell costimulator (ICOS)/cluster of differentiation 28 (CD28) antagonist program for the treatment of autoimmune and inflammatory diseases; ALPN-202, a conditional CD28 costimulator and dual checkpoint inhibitor for the treatment of cancer; and ALPN-303, a dual B cell cytokine antagonist for the treatment of B cell-mediated inflammatory and autoimmune diseases. The company has a collaboration agreement with AbbVie Ireland Unlimited Company for the development of ALPN-101; and Adaptimmune Therapeutics plc to develop next-generation SPEAR T cell products. Alpine Immune Sciences, Inc. was incorporated in 2007 and is headquartered in Seattle, Washington.
Visit WebsiteRating Distribution
Strong Buy
0%
Buy / Outperform
7
100%
Hold / Neutral
0%
Sell / Underperform
0%
Analyst Consensus🟢 Bullish
7 Bullish0 Neutral/Bearish
Price Targets
$25
Average Target
↓ 61.5% Downside
Now
$14
Low
$25
Average
$55
High
Based on 8 analysts
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| April 9th 2024 | Guggenheim | Initiation | Buy | $55 |
| February 15th 2024 | Wolfe Research | Initiation | Outperform | $44 |
| October 18th 2023 | Berenberg | Initiation | Buy | $18 |
| October 17th 2023 | Berenberg | Initiation | Buy | $18 |
| October 5th 2023 | RBC Capital Mkts | Initiation | Outperform | $19 |
| June 26th 2023 | Oppenheimer | Resumed | Outperform | $14 |
| January 19th 2023 | Morgan Stanley | Initiation | Overweight | $17 |
| November 21st 2022 | SVB Leerink | Initiation | Outperform | $15 |
Earnings History & Surprises
ALPNBeat Rate
45%
Last 20 quarters
Avg Surprise
-579.2%
EPS vs Estimate
Beats / Misses
9/10
1 met exactly
Latest EPS
$-0.28
Q2 2024
EPS Surprise History
Q3 22
-53.8%
$-0.60vs$-0.39
Q4 22
-320.0%
$-0.42vs$-0.10
Q1 23
-51.9%
$-0.41vs$-0.27
Q2 23
+24.3%
$-0.28vs$-0.37
Q3 23
+28.9%
$-0.27vs$-0.38
Q4 23
+31.4%
$-0.24vs$-0.35
Q1 24
+135.3%
$0.12vs$-0.34
Q2 24
+34.9%
$-0.28vs$-0.43
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q2 2024 | May 9, 2024 | $-0.43 | $-0.28 | +34.9% | ✓ BEAT |
Q1 2024 | Mar 18, 2024 | $-0.34 | $0.12 | +135.3% | ✓ BEAT |
Q4 2023 | Nov 14, 2023 | $-0.35 | $-0.24 | +31.4% | ✓ BEAT |
Q3 2023 | Aug 14, 2023 | $-0.38 | $-0.27 | +28.9% | ✓ BEAT |
Q2 2023 | May 11, 2023 | $-0.37 | $-0.28 | +24.3% | ✓ BEAT |
Q1 2023 | Mar 23, 2023 | $-0.27 | $-0.41 | -51.9% | ✗ MISS |
Q4 2022 | Nov 14, 2022 | $-0.10 | $-0.42 | -320.0% | ✗ MISS |
Q3 2022 | Aug 11, 2022 | $-0.39 | $-0.60 | -53.8% | ✗ MISS |
Q2 2022 | May 12, 2022 | $-0.17 | $-0.25 | -47.1% | ✗ MISS |
Q1 2022 | Mar 17, 2022 | $-0.26 | $-0.52 | -100.0% | ✗ MISS |
Q4 2021 | Nov 10, 2021 | $-0.00 | $-0.55 | -11101.6% | ✗ MISS |
Q3 2021 | Aug 10, 2021 | $-0.29 | $-0.46 | -58.6% | ✗ MISS |
Q2 2021 | May 13, 2021 | $-0.32 | $-0.45 | -40.6% | ✗ MISS |
Q1 2021 | Mar 18, 2021 | $-0.27 | $-0.27 | 0.0% | = MET |
Q4 2020 | Nov 12, 2020 | $-0.23 | $-0.28 | -21.7% | ✗ MISS |
Q3 2020 | Aug 11, 2020 | $-0.23 | $-0.53 | -130.4% | ✗ MISS |
Q2 2020 | May 14, 2020 | $-0.48 | $-0.30 | +37.5% | ✓ BEAT |
Q1 2020 | Mar 30, 2020 | $-0.55 | $-0.33 | +40.0% | ✓ BEAT |
Q4 2019 | Nov 13, 2019 | $-0.67 | $-0.62 | +7.5% | ✓ BEAT |
Q3 2019 | Aug 13, 2019 | $-0.65 | $-0.64 | +1.5% | ✓ BEAT |
Latest News
Loading news...
Frequently Asked Questions about ALPN
What is ALPN's current stock price?
Alpine Immune Sciences, Inc. (ALPN) is currently trading at $64.97 per share. The stock has moved +0.02% today.
What is the analyst price target for ALPN?
The average analyst price target for ALPN is $55.00, based on 1 analyst.
What sector is Alpine Immune Sciences, Inc. in?
Alpine Immune Sciences, Inc. operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the NASDAQ exchange.
What is ALPN's market cap?
Alpine Immune Sciences, Inc. has a market capitalization of $4.46 billion, making it a mid-cap company.
Does ALPN pay dividends?
No, Alpine Immune Sciences, Inc. does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorASPHF
Ascentage Pharma Group International
$8.48
Mkt Cap: $3.2B
CBAY
CymaBay Therapeutics, Inc.
$32.48
Mkt Cap: $3.7B
CCXI
ChemoCentryx, Inc.
$51.99
0GBT
Global Blood Therapeutics, Inc.
$68.49
0ISEE
IVERIC bio, Inc.
$39.95
Mkt Cap: $5.5B
MRTX
Mirati Therapeutics, Inc.
$58.70
Mkt Cap: $4.1B
RETA
Reata Pharmaceuticals, Inc.
$172.36
Mkt Cap: $6.6B
RYZB
RayzeBio, Inc. Common Stock
$62.49
Mkt Cap: $3.8B
SWTX
SpringWorks Therapeutics, Inc.
$46.99
Mkt Cap: $3.5B
TPTX
Turning Point Therapeutics, Inc.
$75.49
0Explore stocks similar to ALPN for comparison